drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Gene-modified T lymphocytes engineered ex vivo to express a chimeric antigen receptor targeting CD19 with CD3ζ and costimulatory domains; administered as a single IV infusion after lymphodepleting chemotherapy to treat relapsed/refractory CD19+ B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo–engineered T lymphocytes expressing a CD19‑specific chimeric antigen receptor with CD3ζ and costimulatory domains recognize CD19 on B‑cell malignancies and, upon CAR engagement, trigger TCR‑independent activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxicity to eliminate CD19+ tumor cells; prior lymphodepletion supports in vivo expansion and persistence.
drug_name
CD19-directed CAR-T cells
nct_id_drug_ref
NCT06596057